New Prostate Cancer Drug Up For Approval ? CBS Washington

(Credit: Joe Raedle/Getty Images)

WASHINGTON (CBSDC/AP) ? Scientists for the Food and Drug Administration say an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug failed to extend life and carried significant side effects.

The Food and Drug Administration will ask a panel of outside experts on Wednesday whether the benefits of Amgen?s Xgeva (ex-jeev?-ah) outweigh its risks, which included bone disease in about 5 percent of patients taking the drug.

Xgeva is already approved for preventing fractures in cancerous bones, and for osteoporosis, in a different formulation called Prolia.

Now the biotechnology company that?s been around since 1980 has asked the FDA to approve its injectable drug for men with recurring prostate cancer that is at high risk of spreading to the bone. Men must have also attempted and failed treatment with hormone therapy.

(TM and Copyright 2012 CBS Radio Inc. and its relevant subsidiaries. CBS RADIO and EYE Logo TM and Copyright 2012 CBS Broadcasting Inc. Used under license. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed. The Associated Press contributed to this report.)

Source: http://washington.cbslocal.com/2012/02/06/new-prostate-cancer-drug-up-for-approval/

scarecrow festival oklahoma state football oklahoma state football case mccoy case mccoy kristin davis kristin davis